Theravance Biopharma, Inc.
TBPH · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $459,650 | $621,606 | $825,691 | $767,544 |
| - Cash | $37,797 | $39,545 | $298,172 | $89,959 |
| + Debt | $49,820 | $49,159 | $74,122 | $652,075 |
| Enterprise Value | $471,673 | $631,220 | $601,641 | $1,329,660 |
| Revenue | $64,381 | $57,424 | $51,346 | $55,311 |
| % Growth | 12.1% | 11.8% | -7.2% | – |
| Gross Profit | $64,381 | $16,803 | -$12,046 | -$138,346 |
| % Margin | 100% | 29.3% | -23.5% | -250.1% |
| EBITDA | -$38,453 | -$51,648 | -$76,084 | -$232,830 |
| % Margin | -59.7% | -89.9% | -148.2% | -420.9% |
| Net Income | -$56,418 | -$55,193 | $872,132 | -$199,426 |
| % Margin | -87.6% | -96.1% | 1,698.5% | -360.6% |
| EPS Diluted | -1.15 | -1 | -1.26 | -2.87 |
| % Growth | -15% | 20.6% | 56.1% | – |
| Operating Cash Flow | -$11,535 | -$26,997 | -$186,991 | -$207,858 |
| Capital Expenditures | -$332 | -$2,488 | -$572 | -$3,406 |
| Free Cash Flow | -$11,867 | -$29,485 | -$187,563 | -$211,264 |